Jasper Therapeutics, Inc.

NASDAQ: JSPR · Healthcare · Biotechnology

PublicHQ Redwood City, CA · San MateoCIK 0001788028Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 16DQ —GM —SS 40

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$75.8M

Employees

as of 2026-09-21

Market cap

$10.5M

as of 2026-09-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$75.8M-$75.8M2025

Operating income-$83.9M-$83.9M2025

Total assets$35.8M$35.8M2025

Liabilities$31.6M$31.6M2025

Equity$4.2M$4.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Jasper Therapeutics, Inc.’s financial profile?

Jasper Therapeutics, Inc. earned -$75.8M in FY2025 net income.

Peers · Healthcare

Akari Therapeutics, Plc——Intensity Therapeutics, Inc.——AEON Biopharma, Inc.——IN8bio, Inc.——Brainstorm Cell Therapeutics Inc.——Conavi Medical Corp.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B74B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOJeetinder Singh Mahal

SectorHealthcare

IndustryBiotechnology

HeadquartersRedwood City, CA

ExchangeNASDAQ: JSPR

Employees22

IPO date2020-01-10

Latest filings

DEF 14A2026-09-04 8-K2026-08-26 10-Q2026-08-14 8-K2026-08-14 8-K2026-08-03 8-K2026-07-31 8-K2026-07-17 8-K2026-07-16

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.